Trial Profile
Effects of rosiglitazone on cardiovascular parameters in postmenopausal nondiabetic women with or without hormone therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2013
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary) ; Conjugated estrogens; Progesterone congeners
- Indications Cardiovascular disorders; Insulin resistance; Menopausal syndrome
- Focus Biomarker; Pharmacodynamics
- 16 Mar 2013 New trial record